Certara (NASDAQ:CERT) Updates FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.410-0.460 for the period, compared to the consensus earnings per share estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $391.0 million.

Certara Stock Down 0.3 %

Shares of NASDAQ CERT opened at $12.25 on Friday. The stock has a market cap of $1.97 billion, a P/E ratio of -31.41, a P/E/G ratio of 5.39 and a beta of 1.52. The firm has a 50 day moving average price of $14.09 and a 200 day moving average price of $16.05. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26. Certara has a 52-week low of $11.70 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. Analysts expect that Certara will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. JMP Securities reissued a market perform rating on shares of Certara in a research report on Wednesday, July 10th. Barclays dropped their price target on shares of Certara from $18.00 to $16.00 and set an equal weight rating on the stock in a research report on Friday, June 28th. Robert W. Baird dropped their price target on shares of Certara from $19.00 to $18.00 and set a neutral rating on the stock in a research report on Wednesday, August 7th. UBS Group dropped their price objective on shares of Certara from $20.00 to $16.00 and set a neutral rating on the stock in a research report on Wednesday, August 7th. Finally, KeyCorp dropped their price objective on shares of Certara from $23.00 to $20.00 and set an overweight rating on the stock in a research report on Thursday, July 11th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Certara presently has an average rating of Hold and a consensus price target of $17.79.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.